Lead candidate for the treatment of chronic pain

Neuropathic pain therapy point by point

OUR LEAD MOLECULE PN6047 has the ability to become a medicine for the treatment of chronic pain. This is underpinned by the following:

PN6047 is a novel fully patented molecule without any significant toxic effects in preclinical testing. PN6047 can be cost effectively synthesized
PN6047 is highly selective for the delta opioid receptor and does not interact with other receptors, transporters or enzymes studied
PN6047 preferentially signals via Gi proteins compared with arrestin proteins
PN6047 has high potency and efficacy in reducing neuropathic pain in various animal models
PN6047 lacks unwanted morphine-like side-effects, such as analgesic tolerance, drug abuse potential and respiratory depression
PN6047 has an excellent preclinical safety profile lacking CVS/GIT interactions and seizure induction
PN6047 shows no histopathological effects following long-term multiple high dose administration.

THUS, PN6047 can be the drug of choice to combat neuropathic pain and other conditions involving sensory hypersensitivity such as chronic cough and itch.

PN6047 versus conventional

The advantages of PN6047, versus current neuropathic pain medicines are potentially substantial.

vs Conventional Opioids:
Better efficacy in sensory hypersensitivity disorders; no μ-opioids receptor side effects; no analgesic tolerance; no abuse potential.

vs Gabapentin:
No dose adjustment in renal insufficiency patients; no abuse potential; no cytochrome enzyme inhibition so less drug interactions.

vs Amitriptyline:
No cardiovascular complications; lower metabolite exposure; no dose adjustment in hepatic insufficiency patients; no significant food or drug interactions.

Latest news

View all

March 12, 2025

Positive FDA feedback for PN6047

PharmNovo has received positive and constructive feedback from the FDA for its lead drug candidate, PN6047, a selective delta opioid receptor agonist aimed at treating peripheral neuropathy with allodynia. Following a successful pre-IND meeting in January 2025, the FDA provided valuable guidance on the Phase IIa study design and had no critical comments on the CMC or non-clinical data. This paves the way for IND submission by the end of 2025 and a Phase IIa clinical trial application in Europe (Spain, Poland, Czech Republic) by Q3 2025.

Pioneering approach to treat neuropathic pain

February 26, 2025

Pioneering approach to treat neuropathic pain

PharmNovo has recently published an article in MedNous, highlighting the pioneering approach to tackling neuropathic pain without the risks traditionally associated with opioids. The lead candidate, PN6047, targets the delta-opioid receptor – offering pain relief without addiction or sedation. Arrangements for a Phase II trial have now been completed, marking a crucial step toward a safer alternative for millions suffering from chronic pain. With the opioid crisis still a major concern, innovative, non-addictive treatments like PN6047 are more urgent than ever.

PharmNovo live at neurology theme event at RedEye

October 25, 2024

PharmNovo live at neurology theme event at RedEye

Per von Mentzer, CEO, presented PN6047 at the Neurology Event at RedEye on October 23. Take the opportunity to listen to a very interesting live presentation and learn more about PN6047, the unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. PN6047 demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. These findings suggest a promising path forward in the field of pain management.

October 10, 2024

PharmNovo at the LSX Nordic Congress

PharmNovo attended the LSX Nordic Congress in Copenhagen 8-9 October and Per von Mentzer, CEO presented PN6047, a unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. Being one of 68 companies that have recently been awarded by EIC for up to 17.5 MEUR (2.5 MEUR grant and up to 15 MEUR equity) from a total of 969 applicants is a strong validation of the potential of the phase II ready asset PN6047 and of PharmNovo. Take the opportunity to listen to the presentation here: